{
    "xml": "<topic id=\"PHP4049\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/insulin\" basename=\"insulin\" title=\"INSULIN\">\n<title>INSULIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_265\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/insulin\">Insulin</xref>\n</p>\n<data name=\"vtmid\">416978009</data>\r\n<data name=\"vtmid\">417423002</data>\r\n<data name=\"vtmid\">417625002</data>\r\n<data name=\"vtmid\">126210001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_654406860\" title=\"Insulins\">Insulins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34635\" title=\"INSULINS\" namespace=\"/drug-classes/insulins\">INSULINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Insulin Injection; Neutral Insulin; Soluble Insulin</p>\r\n</body>\n<topic id=\"PHP66018\" outputclass=\"indicationsAndDose\" rev=\"1.26\" parent=\"/drugs/insulin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Diabetes mellitus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by intramuscular injection or by intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>According to requirements.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Diabetic ketoacidosis</p>\n<p outputclass=\"therapeuticIndication\">Diabetes during surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65903\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/insulin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67234\" outputclass=\"directionsForAdministration\" rev=\"1.23\" parent=\"/drugs/insulin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.</p>\n<p>Some insulin preparations are not recommended for use in subcutaneous insulin infusion pumps&#8212;may precipitate in catheter or needle&#8212;consult product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> give continuously in Sodium chloride 0.9%. Adsorbed to some extent by plastic infusion set; ensure insulin is not injected into 'dead space' of injection port of the infusion bag.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58798\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.7\" parent=\"/drugs/insulin\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>A sterile solution of insulin (i.e. bovine or porcine) or of human insulin; pH 6.6&#8211;8.0.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64981\" outputclass=\"nationalFunding\" rev=\"1.18\" parent=\"/drugs/insulin\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA151</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008)</p>\r\n<p>Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes: </p>\r\n<ul>\r\n<li>who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, <b>or</b>\r\n</li>\r\n<li>whose glycaemic control remains inadequate (HbA<sub>1c</sub> over 8.5% [69&#8239;mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).</li>\r\n</ul>\r\n<p>Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA151\">www.nice.org.uk/TA151</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP4049-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/insulin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for injection</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76344\" title=\"Solution for injection\" namespace=\"/drugs/insulin/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78144\" namespace=\"/treatment-summaries/acute-coronary-syndromes\" title=\"Acute coronary syndromes\" count=\"1\" rel=\"backlink\">Acute coronary syndromes</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_265\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/insulin\" title=\"Insulin\" count=\"1\" rel=\"link\">Insulin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34635\" namespace=\"/drug-classes/insulins\" title=\"INSULINS\" count=\"1\" rel=\"link\">INSULINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76344\" namespace=\"/drugs/insulin/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP4049",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/insulin",
    "basename": "insulin",
    "title": "INSULIN",
    "interactants": [
        {
            "id": "bnf_int_265",
            "label": "Insulin"
        }
    ],
    "vtmid": "126210001",
    "drugClassification": [
        "Insulins"
    ],
    "inheritsFromClass": [
        "INSULINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Insulin Injection",
        "Neutral Insulin",
        "Soluble Insulin"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Diabetes mellitus",
                        "html": "Diabetes mellitus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection or intramuscular injection or intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By subcutaneous injection or by intramuscular injection or by intravenous injection or by intravenous infusion",
                    "html": "By subcutaneous injection or by intramuscular injection or by intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "According to requirements.",
                        "html": "<p>According to requirements.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Diabetic ketoacidosis",
                        "html": "Diabetic ketoacidosis"
                    },
                    {
                        "textContent": "Diabetes during surgery",
                        "html": "Diabetes during surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.\n\nSome insulin preparations are not recommended for use in subcutaneous insulin infusion pumps&#8212;may precipitate in catheter or needle&#8212;consult product literature.",
                "html": "<p>Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.</p><p>Some insulin preparations are not recommended for use in subcutaneous insulin infusion pumps&#8212;may precipitate in catheter or needle&#8212;consult product literature.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion give continuously in Sodium chloride 0.9%. Adsorbed to some extent by plastic infusion set; ensure insulin is not injected into 'dead space' of injection port of the infusion bag.",
                "html": "<p>For <i>intravenous infusion</i> give continuously in Sodium chloride 0.9%. Adsorbed to some extent by plastic infusion set; ensure insulin is not injected into 'dead space' of injection port of the infusion bag.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "A sterile solution of insulin (i.e. bovine or porcine) or of human insulin; pH 6.6&#8211;8.0.",
                "html": "<p>A sterile solution of insulin (i.e. bovine or porcine) or of human insulin; pH 6.6&#8211;8.0.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA151",
                        "label": "www.nice.org.uk/TA151"
                    }
                ],
                "fundingIdentifier": "NICE TA151",
                "textContent": "Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes: who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate). Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.\n\nwww.nice.org.uk/TA151",
                "html": "<p outputclass=\"title\">Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008)</p> <p>Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes: </p> <ul> <li>who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, <b>or</b> </li> <li>whose glycaemic control remains inadequate (HbA<sub>1c</sub> over 8.5% [69&#8239;mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).</li> </ul> <p>Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA151\">www.nice.org.uk/TA151</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for injection"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76344",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78144",
                "label": "Acute coronary syndromes",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_265",
                "label": "Insulin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34635",
                "label": "INSULINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76344",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}